MedTrace Logo

Study with Norucholic Acid Tablets in Patients with Primary Sclerosing Cholangitis (PSC)

NCT06886360 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2025-03-20

No results posted yet for this study

Summary

Open-label, multi-center, phase III trial. Oral treatment with 1500 mg norucholic acid in Primary Sclerosing cholangitis

Conditions

  • Primary Sclerosing Cholangitis

Interventions

DRUG

norucholic acid

500 mg norucholic acid film-coated tablets; 3 tablets/day

Sponsors & Collaborators

  • Dr. Falk Pharma GmbH

    lead INDUSTRY

Principal Investigators

  • Michael Trauner, MD · Medical University of Vienna, dept. of Internal Medicine III

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-31
Primary Completion
2027-09-30
Completion
2027-09-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06886360 on ClinicalTrials.gov